IDEXX continues to show a high-margin, recurring-revenue profile, with gross margin holding near 63% (62.9% in 2026Q3) and revenue growth moderating from 14.3% in 2026Q1 to roughly 10% in the latest two quarters.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth moderated to roughly 9.9% in 2026Q3 from a 14.3% peak in 2026Q1, while gross margin held near 62.9% and operating margin eased from 35.0% to 33.1%, suggesting profitability remains strong but past its high-water mark.
IDEXX Laboratories is recognized for its dominant position in veterinary diagnostics, which is a key driver of its growth and market appeal.
The company's recurring revenue model provides stable and predictable income streams, enhancing financial stability and investor confidence.
IDEXX Laboratories maintains strong margins, reflecting efficient operations and pricing power in its markets.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $3.96+6.2% vs $3.73 | $1.2B+1.9% vs $1.2B |
Q3 2026 Aug 4, 2026 | $4.27+8.4% vs $3.94 | $1.2B+1.4% vs $1.2B |
Q2 2026 May 5, 2026 | $3.47+1.8% vs $3.41 | $1.1B+2.0% vs $1.1B |
Q1 2026 Feb 2, 2026 | $3.08+5.1% vs $2.93 | $1.1B+1.7% vs $1.1B |
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Michael Lane sold 3,979 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the sale, the executive vice president directly owned 4,076 shares of the company's
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Sharon Underberg sold 8,906 shares of the firm's stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president directly owned 7,169 shares
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward revision of FY26 revenue guidance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.
Benchmark IDXX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for IDEXX Laboratories, Inc. (IDXX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $676.04 | $53.33B | 45.20 | 10.42% | 25.36% | 71.18% | — | |
| $79.40 | $33.29B | 13.15 | 2.28% | 26.15% | 76.4% | 2.52% | |
| $86.05 | $9.8B | 23.00 | 4.03% | 3.07% | 8.83% | — | |
| $25.74 | $12.86B | -88.70 | 6.22% | -2.86% | -2.24% | — | |
| $67.41 | $1.53B | 12.51 | 43.78% | 11.22% | 20% | 0.08% | |
| $11.76 | $2.56B | -45.71 | -2.71% | -6.35% | -2.68% | — |
IDEXX Laboratories, Inc. (IDXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
IDEXX Laboratories, Inc. (IDXX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Aug 4, 2026·SEC
May 15, 2026·SEC
Get notified when IDXX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IDEXX Laboratories, Inc. (IDXX) stock FAQ — growth, dividends, profitability & financials explained
IDEXX Laboratories, Inc. (IDXX) reported $4.66B in revenue over the trailing twelve months. Revenue was $4.30B in fiscal year 2025. That is 1508% more than the $267.7M of fiscal year 1996.
IDEXX Laboratories, Inc. (IDXX) grew revenue by 11.9% over the trailing twelve months, compared with the twelve months before.
Yes. IDEXX Laboratories, Inc. (IDXX) earned $1.18B in net income over the trailing twelve months (a 25.4% net margin).
IDEXX Laboratories, Inc. (IDXX) had a return on equity (ROE) of 71.2% over the trailing twelve months. That is well above the market's typical 10-15%.
IDEXX Laboratories, Inc. (IDXX) generated $1.30B in free cash flow over the trailing twelve months.
